| 61 |
Clinical Research
|
Microbicidal wound dressing with odor control properties First Author: Roy Carr Authors: 1. Bernd Liesenfeld, Ph.D 2. Greg Schultz, Ph.D. 3. Christopher Batich, Ph.D. 4. David Moore, B.Sc. 5. Jillian Vella, B.Sc. 6. Gerald Olderman, Ph.D. R. Carr2, B. Liesenfeld2, G. Schultz1,2, C. Batich1,2, D. Moore2, J Vella2 and J. Olderman2 1University of Florida, Gainesville, FL 2QuickMed Technologies, Gainesville, FL Current commercially available antimicrobial dressings have clearly demonstrated improved healing on chronic wounds, and improved patient outcomes. These dressings also provide barrier functions that can help lower the incidence of nosocomial infection by protecting the wound from pathogens, and by suppressing and containing pathogens residing in wounds. For exudative wounds, dressing changes may be indicated not by medical need but on the basis of social need for odor control from dressings. High cost, potential toxicity, and the possibility of patients developing resistance to leached agents such as silver or antibiotics, has effectively precluded prophylactic use of many antimicrobial dressings. Quick-Med Technologies (QMT) has devised an effective microbicidal treatment for substrate materials including cellulosics (cotton, rayon) as well as more advanced wound dressing substrates such as foams, synthetics, and super-absorbents. The patented NIMBUSª treatment has sufficiently low incremental cost to permit broad use as both primary and secondary dressing material. In vitro testing has demonstrated highly effective microbicidal activity against pathogenic bacteria (including Staphylococcus aureus and epidermidis, Pseudomonas aeruginosa, MRSA, VRE, Escherichia coli), viruses and fungi. In vitro wound models demonstrated suppression of odor based on bacterial metabolism in dressings. Clinical testing is in progress. All FDA required toxicology tests have been passed with the lowest possible results, confirming the safety of the NIMBUS treatment. |
|